Naslov
'The 4th 90': a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis

Autori
Jones, C ; Bremner, S ; Leon, A ; Begovac, Josip ; Apers, L ; Borges, M ; Zekan, Šime ; Teofilo, E ; Garcia, F ; Duracinsky, M ; Whetham, J.

Izvornik
Hiv medicine (1464-2662) 20 (2019), Suppl.9; 211-211

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, ostalo, znanstveni

Ključne riječi
Preliminary assessment ; Quality ; Life ; EmERGE

Sažetak
Purpose: To assess the potential effect on Quality of Life (QoL) of a codesigned reduced visit pathway of care for individuals living with stable HIV. Methods: People living with stable HIV across five diverse clinical sites in Europe were invited to take part in the EmERGE study - whereby individuals are seen once instead of twice a year by their clinician - with interim visits supported via an mHealth platform. We report descriptively on QoL outcomes at baseline (M0) and month12 (M12) available to May 2019. For PROQOL-HIV, the mean change in score is reported by domain. For EQ-5D-5L, some vs. no problems (as proportions) are reported by dimension. Results: PROQOL-HIV was completed by N=1868/2230 (83.8%) at M0 and 966/1439 (69.2%) at M12. At M0, domain scores were generally high across sites (median score for each≥75/100), except for stigma (median=50, IQR 25.0–87.5) with some variation by site. Mean differences (M12-M0) for all domains were small relative to their SDs, indicating little change. Participants’ general health was good at M0, (2.4% rated their health as <fair) and at M12 had improved for N=151/912(16.6%), worsened for 261(28.6%), unchanged for 500 (54.8%). EQ-5D-5L was available on N=2115/2230 (95.5%) at M0, and N=1018/1439(70.1%) at M12. Mean health today was 84.3(SD=13.1), M0, and 83.4(SD=13.7), M12. At both M0&M12, >75% of respondents reported no problems with mobility, self-care or usual activities ; a smaller majority reported no pain/discomfort or anxiety/depression: proportions for these domains were lower (8.8%&6.6%, respectively) at M12. Conclusions: Preliminary results show QoL was high across PROQOL-HIV domains, except stigma, which scored lowest. Changes over time were small ; stigma improved at four out of five sites. QoL was similarly high on EQ-5D-5L dimensions. Observed reductions in general health and/or QoL may be explained by a ceiling effect in this healthy population with high QoL.

Izvorni jezik
Engleski

POVEZANOST RADA